141. Predicting mycophenolic acid exposure in paediatric lupus nephritis: a real-world study across three clinical scenarios.
作者: Baojing Liu.;Lizhi Chen.;Yuqi Wang.;Jingxuan Lin.;Yutong Guo.;Kejing Tang.;Xiaoyun Jiang.;Pan Chen.
来源: Rheumatology (Oxford). 2026年65卷3期
Childhood-onset systemic lupus erythematosus (cSLE) with lupus nephritis (LN) presents therapeutic challenges due to complex mycophenolic acid (MPA) pharmacokinetics. This study developed machine learning (ML)-based models to predict MPA area under the concentration-time curve (MPA-AUC) across three scenarios: determining therapeutic window attainment, precise AUC estimation and forecasting post-dose-adjustment exposure.
142. Machine-learning algorithms for predicting colchicine resistance in Familial Mediterranean Fever.
作者: Admir Ozturk.;Berkay Kilic.;Murad Kucur.;Lara Yagci.;Serdal Ugurlu.
来源: Rheumatology (Oxford). 2026年65卷3期
FMF is a genetic autoinflammatory condition marked by recurrent fever and serositis. Colchicine is the mainstay treatment. However, 5% to 10% of patients exhibit colchicine resistance, requiring alternative therapies. Early identification of resistance is vital. While some scoring systems exist for paediatric FMF, artificial intelligence's (AI's) potential to predict colchicine resistance in adult patients with FMF has not been systematically explored. This study aimed to utilize machine-learning (ML) and deep-learning (DL) algorithms to predict colchicine resistance in adult patients with FMF.
143. Identification of clinical phenotypes and disease trajectories in SLE using AI through a natural language processing framework.
作者: Silvia Laura Bosello.;Augusta Ortolan.;Lucia Lanzo.;Livia Lilli.;Laura Antenucci.;Pier Giacomo Cerasuolo.;Silvia Piunno.;Luca Petricca.;Maria Rita Gigante.;Viviana Antonella Pacucci.;Marco Gorini.;Gabriella Castellino.;Carlotta Masciocchi.;Jacopo Lenkowicz.;Stefano Patarnello.;Maria Antonietta D'Agostino.
来源: Rheumatology (Oxford). 2026年65卷2期
Electronic health records (EHRs) contain a wealth of unstructured patient data that can be leveraged using artificial intelligence (AI). This study aimed to develop a natural language processing (NLP) pipeline to identify clinical phenotypes and disease trajectories in patients with systemic lupus erythematosus (SLE) from EHRs.
146. Serum type I interferon promotes AIM2 inflammasome dysregulation in lupus patients through STAT1 and STAT2.
作者: Jia Xin Chow.;Huan Zhu.;Jiao Jiang.;Jie Ma.;Chung Sze Or.;Mengqi Yang.;Haijing Wu.;Chak Sing Lau.;Vera Sau Fong Chan.
来源: Rheumatology (Oxford). 2026年65卷3期
The Absent in Melanoma 2 (AIM2) inflammasome is a crucial producer of IL-1β and IL-18 upon sensing double-stranded (ds)DNA but its role in SLE remains ambiguous. The study aims to investigate the involvement and underlying mechanism leading to AIM2 inflammasome dysregulation in lupus patients.
147. Lipoid proteinosis mimicking Sjögren's syndrome: a diagnostic challenge in rheumatology practice.
作者: Mehmet Akif Baltaci.;Elifcan Taşdelen.;Gokhan Toptas.;Melih Pamukcu.;Esin Kurtulus Ozturk.;Ozlem Ozmen.;Murat Alper.;Ertugrul Cagri Bolek.
来源: Rheumatology (Oxford). 2026年65卷2期 148. Rheumatoid arthritis and interstitial lung disease: the role of comorbidities. Retrospective analysis of two RA inception cohorts in the UK.
作者: Rositsa Dacheva.;Amanda Busby.;Patrick Kiely.;Adam Young.;David A Walsh.;Daniel F McWilliams.;James Galloway.;Elena Nikiphorou.
来源: Rheumatology (Oxford). 2026年
To assess the role of comorbidities measurements in interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA).
149. Measurement properties of the Polymyalgia Rheumatica Activity Score (PMR-AS): reliability, measurement error and discriminative validity.
作者: Noortje E S E P Kooijman.;David F Ten Cate.;Pauline M E T Bovens.;Maike H M Wientjes.;Claire E Owen.;Alfons A den Broeder.;Aatke van der Maas.
来源: Rheumatology (Oxford). 2026年65卷2期
The Polymyalgia Rheumatica Activity Score (PMR-AS) is the best validated composite disease activity measure in PMR to date, but its reliability, measurement error and discriminative validity have not been studied.
150. Can we use patient-reported outcomes for remote monitoring in SSc?
作者: Eva M Hoekstra.;Katherine E van der Wouden.;Queeny S R Madari.;Saad Ahmed.;Lianne E Kwant.;Ada Hortensius-Varkevisser.;Emiel R Marges.;Jacopo C Ciaffi.;Anne Schouffoer.;Tom W J Huizinga.;Jeska K de Vries-Bouwstra.
来源: Rheumatology (Oxford). 2026年65卷2期 152. Current perspectives on biomarkers to safely guide reduction and withdrawal of immunosuppressants in lupus nephritis.
With new insights into damage accrual, new outcome measures and new therapies emerging, treatment for lupus nephritis (LN) has evolved over the last years. Although a greater proportion of patients shows clinical responses, treatment reduction and withdrawal remain challenging. While immunosuppressive therapy has relevant side effects, relapses pose the risk of long-term kidney function impairment. Unlike other autoimmune kidney diseases, LN lacks a unique biomarker or biomarker profile clearly reflecting disease activity. Here, we review definitions of remission, LN immunosuppressant withdrawal studies and new biomarkers correlated with disease activity. These factors can help to identify patients who can be safely withdrawn from immunosuppression reducing risk of infection, cardiovascular side effects, toxicity and damage accrual.
153. Objective and subjective sleep assessment in systemic lupus erythematosus and association with disease characteristics and quality of life.
作者: Anushka Aggarwal.;Shiri Keret.;Rohini Handa.;Sundeep Upadhyaya.;Sirinder J Gupta.
来源: Rheumatology (Oxford). 2026年65卷3期
Sleep disturbances significantly impact quality of life (QoL) in systemic lupus erythematosus (SLE). This study aimed to assess sleep quality in cases and controls using both subjective and objective measures and explore association with disease characteristics, psychological factors, physical function and QoL.
154. Pain mechanisms in PsA: differentiating inflammation-related pain in Achilles enthesitis using US and functional MRI.
作者: Ummugulsum Gazel.;Kristen Noges.;Burak Ayan.;Gizem Ayan.;Olivier Brown.;Andra Smith.;Sibel Zehra Aydin.
来源: Rheumatology (Oxford). 2026年65卷2期
Pain in PsA is common and multifactorial, involving nociceptive, neuropathic and nociplastic mechanisms. We hypothesized that PsA patients with entheseal pain exhibit distinct brain activation patterns on functional MRI (fMRI), depending on the presence of US-detected inflammation.
155. Assessing digital vasculopathy in systemic sclerosis.
Digital vasculopathy (a spectrum of Raynaud's phenomenon, digital ulceration and critical ischaemia) is one of the most characteristic manifestations of systemic sclerosis (SSc). It is an area of unmet need with a major impact on quality of life: current treatments are only poorly effective. SSc-related digital vasculopathy is a result of structural as well as functional change at the level of both the microcirculation and the digital artery, explaining its severity. This review begins with a brief description of digital vasculopathy, followed by its assessment in the clinical setting, relevant to both diagnosis and monitoring of SSc. Outcome measures of Raynaud's phenomenon and of digital ulcers are then discussed, focusing on recent advances. These outcome measures are a 'hot topic' because reliable patient-reported and laboratory-based outcome measures will facilitate much needed clinical trials. Finally, some of the emerging non-invasive technologies which are providing new insights into pathophysiology are briefly described.
156. Comment on: Long-term effects of selexipag in SSc-associated digital ulcers: a case-control multicentre observational study: reply.
作者: Claudia Iannone.;Marco Di Battista.;Maria Rosa Pellico.;Ilaria Magi.;Antonina Minniti.;Giuseppe Armentaro.;Silvia Cavalli.;Manuel Sette.;Laura Giudice.;Cristina Bochicchio.;Alessandra Della Rossa.;Antonio G Tavoni.;Fabio Cacciapaglia.;Stefano Stano.;Martina Orlandi.;Dilia Giuggioli.;Marta Mosca.;Roberto Caporali.;Nicoletta Del Papa.
来源: Rheumatology (Oxford). 2026年65卷2期 157. Building bridges for early-career rheumatologists in Türkiye: insights from the Turkish Society for Rheumatology-young rheumatologists.
作者: Ertugrul Cagri Bolek.;Gizem Ayan.;Emre Bilgin.;Ufuk Ilgen.;Mert Oztas.;Yasemin Kabasakal.;Fatos Onen.;Sedat Kiraz.
来源: Rheumatology (Oxford). 2026年65卷2期 158. Advancing drug development for systemic sclerosis by prioritizing findings from human genetic association studies.
作者: Michael Hughes.;Zsuzsanna H McMahan.;Shervin Assassai.;Christopher P Denton.;Rui Providencia.
来源: Rheumatology (Oxford). 2026年65卷3期
SSc is a rare rheumatological disease associated with significant morbidity and mortality. Despite significant recent international clinical trial activity, the yield of approved compounds has been disappointingly low. Our aim was to identify and prioritize potential 'druggable' targets with insights from human genetics, by integrating the available evidence with publicly available bioinformatics sources relevant for SSc drug development.
159. Prevalence of effective contraceptive use among patients with rheumatic diseases: a descriptive study.
作者: Mayalen Uthurriague.;Charlotte Delattre.;Thomas Barnetche.;Estibaliz Lazaro.;Marie-Elise Truchetet.;Claude Hocke.;Nadia Mehsen-Cetre.;Valérie Bernard.;Christophe Richez.
来源: BMC Rheumatol. 2026年10卷1期
Systemic autoimmune and chronic inflammatory rheumatic diseases predominantly affect childbearing women. These women are at greater risk for pregnancy complications stemming from both the underlying disease and the treatments required to manage it. This cross-sectional study aimed to assess the prevalence of effective contraceptive use across a wide range of diseases including systemic lupus, systemic sclerosis, Sharp syndrome, Sjögren’s disease, rheumatoid arthritis, and spondyloarthritis.
160. Artificial Intelligence (AI) in rheumatology: a comparative evaluation of the ChatGPT and DeepSeek application.
The continuous increase in Artificial Intelligence (AI) applications in various areas of human life has brought about great changes in many sciences, among which is the health sector. ChatGPT and DeepSeek belong to the category of Large Language Models (LLMs) developed by Artificial Intelligence (AI) using supervised and reinforcement learning techniques. The aim of this article is to evaluate the accuracy and consistency of ChatGPT and DeepSeek models in the diagnosis and treatment of two rheumatologic diseases, ankylosing spondylitis (axSpA) and psoriatic arthritis (PsA).
|